June 2018 Vol 9, No 6

We enthusiastically present a “crosswalk” reference demonstrating the synergy between the AONN+ metrics and national oncology standards and indicators.
A thoughtful discussion on the development of the AONN+ metrics and the need to identify how these measures align with the national standards and indicators.
A maintenance regimen of lenalidomide (Revli-mid) and elotuzumab (Empliciti) after autologous stem cell transplant (ASCT) improved the quality of responses achieved with induction therapy in patients with multiple myeloma.
People from lower socioeconomic backgrounds, minority groups, and rural areas are not well represented in clinical trials and biobanking, hampering research on health disparities.

Results 1 - 5 of 5

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State